Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 907 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mental and Behavioural Disorders Clear all
Completed Not applicable Interventional Results available

Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study

NCT06305078
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Personalized ADHD Medication Experiment
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 10, 2026, 8:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Multisite Prevention of Conduct Problems (Fast Track)

NCT01653535
View directory record Official record
Conditions
Conduct Disorder, Anti-Social Behavior
Interventions
Fast Track
Behavioral
Lead sponsor
Duke University
Other
Eligibility
6 Years to 8 Years
Enrollment
891 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 3 Interventional Results available

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsule, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 3 Interventional

Dasotraline Adult ADHD Study

NCT02276209
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
59
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 10, 2026, 8:13 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

NCT04296604
View directory record Official record
Conditions
Traumatic Brain Injury, Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder, Borderline Personality Disorder, Substance Use Disorders
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 2 Interventional

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

NCT00414921
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
clonidine, methylphenidate, placebo
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
4 Years to 6 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2009 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Not applicable Interventional Results available

Communication to Improve Shared Decision-Making in ADHD

NCT02716324
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Care Manager CM), ADHD Portal
Behavioral · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 12 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Not applicable Interventional Results available

Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD)

NCT03663179
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity (ADHD)
Interventions
Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (Sham TMS)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 10, 2026, 8:13 PM EDT
Recruiting Not applicable Interventional

Spanish-language Executive Function Intervention for Children With Autism and/or ADHD

NCT07084324
View directory record Official record
Conditions
Autism, ADHD
Interventions
Unstuck and On Target
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

NCT03675282
View directory record Official record
Conditions
Parkinson Disease, REM Sleep Behavior Disorder, Healthy
Interventions
(11C)PE2I, Ioflupane
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 100 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 10, 2026, 8:13 PM EDT
Recruiting No phase listed Observational

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

NCT07389473
View directory record Official record
Conditions
ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized, Bipolar Disorder (BPD)
Interventions
Prescription Psychotropic Medications
Drug
Lead sponsor
Gaize
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 3 Interventional

Open-label Safety Study in Adults With ADHD

NCT02160262
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
65
States / cities
Beverly Hills, California • Encino, California • Escondido, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 10, 2026, 8:13 PM EDT
Recruiting Not applicable Interventional

Regulating Emotions Like An eXpert Among Adolescents With ADHD

NCT06725186
View directory record Official record
Conditions
RELAX Telehealth Intervention, Psychoeducational Waitlist Control, EMI Smartphone App Pilot
Interventions
RELAX, Psychoeducational Materials
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
11 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 2 Interventional

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

NCT07253441
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN XR (TBM), CTN SR, CTN XR (Clin)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Lenexa, Kansas • Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 10, 2026, 8:13 PM EDT
Terminated Phase 3 Interventional

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

NCT06431256
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
4 Years to 5 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Dothan, Alabama • Anaheim, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Tailored Occupational Therapy Intervention for Women With ADHD

NCT03203928
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Occupational Therapy Intervention for Women with ADHD
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 55 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 10, 2026, 8:13 PM EDT
Terminated Phase 4 Interventional Results available

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

NCT02170298
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

NCT00421603
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Not applicable Interventional

Mindful Awareness Practices for ADHD Pilot Open Trial

NCT05584475
View directory record Official record
Conditions
ADHD
Interventions
Mindful Awareness Practices (MAPs)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

NCT00343811
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 10, 2026, 8:13 PM EDT
Terminated Not applicable Interventional Results available

Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

NCT00745030
View directory record Official record
Conditions
REM Behavior Disorder, Parkinsonism
Interventions
Rozerem, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552902
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
81
States / cities
Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 10, 2026, 8:13 PM EDT
Completed Phase 4 Interventional Results available

Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA

NCT00434213
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daytrana
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Scottsdale, Arizona • Irvine, California • San Marcos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 10, 2026, 8:13 PM EDT